Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2022 - 05 - 23 save search
Global Clinical Trial Management System (CTMS) Market Report 2022-2027: Breakdown by Pharmaceutical and Biotechnology Companies, Contract Research Organizations, & Medical Device Manufacturers
Published: 2022-05-23 (Crawled : 18:00) - prnewswire.com
ORCL | News | $117.87 -0.67% 1.9M
|
Technology Services
|
| O: 0.82%
H: 0.0%
C: 0.0%
management device research system report contract trial market
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | $165.54 0.78% 2.2M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
JNJ | News | $144.54 -0.16% 4.9M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
DRTS | $2.69 92K
|
n/a
|
| O: -1.29%
H: 19.57%
C: 7.49%
skin trial dart cancer
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
ASND | $143.085 0.64% 61K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial china positive results phase 3
Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
TSOI | $0.0007 13M
|
Manufacturing
|
| O: 1.27%
H: 0.0%
C: -5.83%
fda disease solutions trial international
RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
RAPT | $8.02 -0.25% 230K
|
Health Technology
|
| O: 1.19%
H: 0.0%
C: -7.65%
rpt193 dermatitis trial therapeutics phase 2b
Day One Announces First Patients Dosed in Phase 1b/2 Combination Study with Tovorafenib (DAY101) and Pimasertib in RAF-altered Solid Tumors
Published: 2022-05-23 (Crawled : 14:00) - biospace.com/
DAWN 4 | $15.71 5.79% 1.1M
|
Professional, Scientific, and T...
|
| O: 1.81%
H: 5.87%
C: -1.5%
day101 day one phase 2b
Elicio Touts "Huge Potential" for Cancer Vaccine Following Preclinical Data
Published: 2022-05-23 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: 0.0%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
preclinical vaccine cancer pre-clinical potential
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis
Published: 2022-05-23 (Crawled : 14:00) - biospace.com/
REVB | $2.15 58K
|
|
| O: 0.53%
H: 8.77%
C: -1.74%
treatment
Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
LMNL | $8.5 0.12% 0.12% 0
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: -11.86%
trial phase 1
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
tukysa topline trial positive results cancer her2- phase 2 her2
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
ARMP | $2.722 8.88% 14K
|
Health Technology
|
| O: -1.88%
H: 1.92%
C: 1.92%
sa02 phase 2b staphylococcus aureus
Clinical Catch-Up: Amgen, AstraZeneza, Avillion Attack Asthma
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
JNJ | News | $144.54 -0.16% 4.9M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -3.11%
H: 0.0%
C: 0.0%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
bnd-22 trial phase 1
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022
Published: 2022-05-23 (Crawled : 12:00) - prnewswire.com
MITO | $0.32 0.25%
|
Health Technology
|
| O: -5.51%
H: 5.7%
C: 1.77%
elamipretide trials phase 2
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $144.675 -0.44% 130K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
cardiac results phase 3
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 6.07%
H: 8.26%
C: -13.24%
ctp-543 topline trial positive phase 3
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $42.77 -2.86% 2.1M
|
Health Technology
|
| O: 0.25%
H: 1.91%
C: 0.92%
trial phase 3
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
PYPD | $4.44 4K
|
Health Technology
|
| O: 2.54%
H: 4.77%
C: -3.24%
trial enroll phase 3
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.